Earnings Scheduled For August 10, 2022
Companies Reporting Before The Bell
• Wix.com (NASDAQ:WIX) is estimated to report earnings for its second quarter.
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 120 companies achieved new lows for the year.
Oncocyte Enters $2B Market With Transplant Rejection Monitoring Test
Oncocyte Corporation (NASDAQ:OCX) completed the development and clinical validation of the Laboratory Test for its newly-branded VitaGraft Transplant Monitoring tests for…
Oncocyte Presents DetermaIO Data At ASCO 2022 Supporting Test’s Potential To Expand Clinical Use Of Immunotherapy
Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey,
Piper Sandler Maintains Overweight on OncoCyte, Lowers Price Target to $1.4
Piper Sandler analyst David Westenberg maintains OncoCyte (NASDAQ:OCX) with a Overweight and lowers the price target from $1.8 to $1.4.
Needham Maintains Buy on OncoCyte, Lowers Price Target to $2.25
Needham analyst Mike Matson maintains OncoCyte (NASDAQ:OCX) with a Buy and lowers the price target from $4 to $2.25.
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell
• Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron’s COVID-19 Therapy Decision Pushed, Protagonist’s Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Piper Sandler Maintains Overweight on OncoCyte, Lowers Price Target to $1.8
Piper Sandler analyst David Westenberg maintains OncoCyte (NASDAQ:OCX) with a Overweight and lowers the price target from $3.1 to $1.8.